address
pemphigus study

CLINICAL RESEARCH STUDY FOR ADULTS WITH PEMPHIGUS VULGARIS OR PEMPHIGUS FOLIACEUS

Are you or a loved one living with Pemphigus (vulgaris or foliaceus) and interested in learning more about a clinical study? You may be eligible to participate in the ADDRESS clinical research study. The ADDRESS study is evaluating the safety and effectiveness of an investigational agent referred to as efgartigimod. Qualified participants will receive study related care at no cost.

PARTICIPATION REQUIREMENTS:

You or a Loved One May Qualify If You:

- Are aged 18 or above
- Have been diagnosed with moderate to severe pemphigus vulgaris or pemphigus foliaceus (also called superficial pemphigus). Other types of pemphigus are excluded from the study.
- Do not have other serious medical conditions and have not recently undergone surgery.

WHAT IS PEMPHIGUS?

Pemphigus is a rare dermatological condition characterized by blistering of skin and mucous membranes. There are many types of pemphigus, but two more prominent types are pemphigus vulgaris and pemphigus foliaceus. In subjects with pemphigus vulgaris, blisters typically appear on the skin or in the mouth. With pemphigus foliaceus, blisters may appear on the scalp, face, or torso but do not usually affect mucous membranes, so pemphigus foliaceus blisters will not appear in the mouth or eyes.

INTERESTED IN LEARNING MORE?

Contact Dr. Naveed Sami, Principal Investigatoror

Dr. Amoy Fraser, Manager-Clinical Trials, 407 COM TRIALS

Amoy.Fraser@UCF.edu

argenx BV_ARGX-113-1904_ADDRESS_PatientFlyer_V3_R1_15FEB2021_USAspecific

ABOUT THE ADDRESS STUDY

This clinical study will evaluate the effectiveness, safety, and tolerability of the investigational agent efgartigimod when administered by subcutaneous injection, for adults with moderate to severe pemphigus vulgaris (PV) or pemphigus foliaceus (PF) who have been diagnosed with either pemphigus vulgaris or pemphigus foliaceus by a physician.

This study is a randomized, double-blind, placebo-controlled study. This means that some study participants will receive investigational agent, while other participants will receive placebo. The placebo will look exactly like the investigational agent but will not have active ingredients. This study will last up to 41 weeks, and study participants will be eligible to participate in an open-label extension study using the same investigational agent. Study participants who are given the placebo will be eligible to receive the investigational agent during the open-label extension study.

Efgartigimod is an investigational agent that has not been approved by any regulatory agency.

Sources - https://mayocl.in/2ZPjjCs